AP NEWS

Pradaxa (dabigatran; Boehringer Ingelheim) Drug Overview 2018 - ResearchAndMarkets.com

May 14, 2018

DUBLIN--(BUSINESS WIRE)--May 14, 2018--The “Drug Overview: Pradaxa” report has been added to ResearchAndMarkets.com’s offering.

Pradaxa (dabigatran; Boehringer Ingelheim) is an orally available direct thrombin inhibitor (factor IIa inhibitor) indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who previously received treatment with a parenteral anticoagulant for five to 10 days. Pradaxa acts by inhibiting the conversion of fibrinogen into fibrin during the coagulation cascade, and therefore does not allow for the stimulation of platelet activation. Further, through thrombin inhibition, Pradaxa prevents the development of thrombus. Taken together, the drug prevents the formation of blood clots.

Key Topics Covered:

OVERVIEW

Drug Overview

Product Profiles

Pradaxa: Stroke prevention in atrial fibrillation (SPAF)

Pradaxa: Venous thromboembolism (VTE)

List of Figures

Figure 1: Pradaxa for SPAF - SWOT analysis

Figure 2: Drug assessment summary of Pradaxa for SPAF

Figure 3: Drug assessment summary of Pradaxa for SPAF

Figure 4: Pradaxa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Pradaxa for venous thromboembolism - SWOT analysis

Figure 6: Drug assessment summary of Pradaxa for venous thromboembolism

Figure 7: Drug assessment summary of Pradaxa for venous thromboembolism

Figure 8: Pradaxa sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Pradaxa drug profile

Table 2: Pradaxa pivotal trial data in SPAF

Table 3: Pradaxa late-phase trial data in SPAF

Table 4: Pradaxa ongoing late-phase clinical trials in SPAF

Table 5: Pradaxa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 6: Pradaxa drug profile

Table 7: Pradaxa pivotal trial data in venous thromboembolism

Table 8: Pradaxa late-phase trial data in venous thromboembolism

Table 9: Pradaxa ongoing late-phase clinical trials in venous thromboembolism

Table 10: Pradaxa sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/kmgdvm/pradaxa?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514006286/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 03:32 PM/DISC: 05/14/2018 03:32 PM

http://www.businesswire.com/news/home/20180514006286/en

AP RADIO
Update hourly